Where Early-Stage Healthcare Innovation Is Being Funded Now

CHART OF THE WEEK 📈

By Teddy Lyons | Read

Healthcare and pharma startups are turning to Regulation Crowdfunding (RegCF) in record numbers—and investors are responding. In today’s Chart of the Week, we examine why RegCF is booming in healthcare while RegA+ faces mounting headwinds, and what it means for investors seeking early-stage innovation opportunities.

Want the full story and takeaways? To view the complete analysis, including healthcare in RegA+, read the full article for free on Kingscrowd HERE.

Have a suggestion for a data story you’d like us to look into? Submit by replying to this email

KINGSCROWD PODCAST

By Sam Fiske / Watch | Apple | Spotify

This week, Kingscrowd founder & CEO Chris Lustrino joins the podcast to unpack the strategic vision behind the recent acquisition of CrowdCheck. Learn how combining Kingscrowd’s powerful data analytics with CrowdCheck’s regulatory expertise creates an end-to-end solution for founders navigating capital raises. Chris also reveals key product launches coming soon, including a robust investor relations platform.

WEBINAR WEDNESDAY: INVESTING IN PRIVATE CREDIT

Private Credit Investing, Demystified
How do you build yield while protecting downside? Carofin’s VP Nash Roberts will explain how direct lending works — and how investors can participate. With special guest, SnippetSentry CRO Jeremiah Smith. Live on April 30th at 3pm ET.

PITCH REVIEW 💸

By Teddy Lyons \ Deal Report

Brief: SportsVisio makes an AI-powered app that provides sports analytics and video highlights to players, coaches, and parents, making pro-level tools accessible to everyone. With over 15,000 users and $800,000 in ARR after growing from $10,000 in a year, SportsVisio is scaling rapidly.

Teddy’s Take: I met the CEO of SportsVisio earlier this year at a Kingscrowd meetup, and discussed crowdfunding with him as a viable option to fill out his funding round. While I tried to play it cool, my inner child was bubbling with excitement over this product…and I really wanted to invest. I have played competitive soccer my entire life, including getting recruited to a few colleges and ultimately playing at a small liberal arts college in Connecticut.

One of my biggest pain points during the recruiting process was sifting through game film to find my “best moments” of every game…a long, tedious process that made me want to rip my hair out. SportsVisio uses AI to create highlight reels and aggregate player stats from uploaded game footage, currently offering solutions for basketball and volleyball (soccer and baseball or next). In full transparency, I uploaded some soccer game footage to ChatGPT and told it to make a highlight reel for one player. It was…decent. But it took over 24 hours for GPT to complete the task. I’m sure SportsVisio’s solution is far quicker, accurate and user-friendly. However, given I was able to do something similar on ChatGPT, my analysis will revolve around whether a 10X improvement in ChatGPT will replace solutions like this in 3-5 years.

STAFF PICKS 🌶️

FluidForm Bio

By Teddy Lyons

3D bioprinting is a new area of study for me. I didn’t actually know it was possible to 3D print live tissue. Now I’m hooked on the idea. FluidForm is the first bioprinting company I’ve come across - they are 3D printing insulin-producing tissue implants for diabetes patients. How close are they to commercialization?

LifeBridge Innovations

By Teddy Lyons

Biotech companies developing new cancer treatments have always intrigued me, particularly ones with clinical data (Oncolyze was my first portfolio exit). LifeBridge “unmasks” cancer cells to patients' immune systems, causing cancer death and tumor reduction using electric fields. Is there enough preclinical data to make this an investable company?

Enjoyed this newsletter? Forward it to an investing-minded friend and have them signup here.